Let’s Do This Thing!
Just over 20 years old, this field has captivated the world with its hopeful promises — and drawn critics for its moralizing, mysticism, and serious commercialization. (Vox)
UC Berkeley synthetic biologists have engineered brewer’s yeast to produce marijuana’s main ingredients—mind-altering THC and non-psychoactive CBD—as well as novel cannabinoids not found in the plant itself.Berkley College of Chemistry
Feeding only on sugar, the yeast are an easy and cheap way to produce pure cannabinoids that today are costly to extract from the buds of the marijuana plant, Cannabis sativa.
Might be time to sell those pot stocks people 😉
The DEA insists it supports medical marijuana research, but it has resisted calls to reclassify the plant so it’s not lumped in with addictive drugs like heroin and ecstasy. When the DEA did in 2016 take steps to expand the supply for scientists, then-Attorney General Jeff Sessions withheld final approval. Several bipartisan bills aimed at expanding research were introduced in the outgoing Congress, but none made it through.Politico
Maybe I’m going out on a limb here — scientists should be free to study nature and its effects on humans.
Although psilocybin is relatively less harmful than other drugs and not prone to compulsive abuse, the researchers don’t recommend releasing psilocybin into patients’ hands even with a prescription. “We believe that the conditions should be tightly controlled and that when taken for a clinical reason, it should be administered in a health care setting, monitored by a person trained for that situation,” says Johnson. The researchers foresee that the process for psilocybin use in the clinic would be similar to how an anesthesiologist prescribes and administers a drug, minimizing the potential for abuse or harm.
Well apparently people have been doing this wrong for 10,000 years and now it needs to be handed over to “pharmaceutical professionals.”
Anecdotal and historical accounts of pot’s painkilling properties abound. But so far, scientific evidence that it works better than traditional painkillers is hard to come by.
Because the U.S. government classifies marijuana as a Schedule 1 drug with no medical use — like heroin and cocaine — funding for research is hard to get, scientists say. And as a 2015 article in the journal Current Pain and Headache Reports points out, high-quality clinical studies of pot’s effectiveness — randomized, double-blind and placebo-controlled — are limited.
Dr. Jeffrey Chen wants to change that.